Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEDTRONIC PLC

(MDT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

First Gynecological Procedures Performed with Medtronic Hugo™ Robotic-Assisted Surgery System

07/29/2021 | 09:00am EDT

Medtronic plc announced the first gynecological procedures with the Hugo™ robotic-assisted surgery (RAS) system. The six cases included hysterectomies and myomectomies performed by Salomón Zebede, M.D., and Juan Carlos López, M.D., last week at Pacifica Salud Hospital in Panama City, Panama. Globally, more than 60% of hysterectomies are performed as open procedures,1 even though minimally invasive surgery offers fewer complications, shorter hospital stays, and faster return to normal activities. Pacifica Salud is the latest institution to join Medtronic's Partners in Possibility Program, a group of pioneering hospitals that will be among the first in the world to use the Hugo RAS system. Earlier this month, the hospital announced its first five urological cases with the Hugo RAS system. Pacifica Salud is also an early adopter of Touch Surgery™ Enterprise, a cloud-based surgical video capture solution that allows surgeons to seamlessly record, analyze, and share surgical video. The Hugo RAS system — Medtronic's solution to historic cost and utilization barriers that have kept surgical robotics out of reach for many hospitals — is a modular, multi-quadrant platform designed for a broad range of soft-tissue procedures. In June, Medtronic announced the first clinical procedures with the Hugo system took place in Santiago, Chile. That marked the beginning of the Hugo RAS system patient registry, which is collecting clinical data to support regulatory submissions around the world. Medtronic has a longstanding history of making a positive impact on women's health through technology. The Hugo RAS system joins a portfolio of gynecological products designed to enable less invasive surgical treatment of a range of conditions including abnormal uterine bleeding, uterine fibroids, and endometrial cancer. The Hugo RAS system is not cleared or approved in the U.S. or Europe. Regulatory requirements of individual countries and regions will determine availability and approval or clearance timelines. Touch Surgery Enterprise is available in the U.S. and Europe; it is not intended to direct surgery, or aid in diagnosis or treatment of a disease or condition.


© S&P Capital IQ 2021
All news about MEDTRONIC PLC
03:45pMEDTRONIC : Enrolls First Patient in Pediatric Trial for Treatment of Scoliosis
MT
03:31pMEDTRONIC : U.S. Patent Office Completes Review of Medtronic Patents, Rejects More Axonics..
PR
10:01aMEDTRONIC : Begins Pediatric Clinical Trial of Spinal Tether for Treatment of Scoliosis
AQ
09/15MEDTRONIC : BofA Global Healthcare Conference 2021
PU
09/14Medtronic to Seek Acquisitions
CI
09/14MEDTRONIC : Says US Patent Office Rejects Axonics' Challenge to Bladder Device Patents
MT
09/13MEDTRONIC : U.S. Patent and Trademark Office Rejects Axonics' Challenge to Medtronic Paten..
PR
09/13MEDTRONIC : Collaboration with Mpirik to Address Disparities in Care Associated with Sudde..
PR
09/13Medtronic Collaboration with Mpirik to Address Disparities in Care Associated with Sudd..
CI
09/10MEDTRONIC PLC : Regulation FD Disclosure (form 8-K)
AQ
More news
Analyst Recommendations on MEDTRONIC PLC
More recommendations
Financials (USD)
Sales 2022 32 991 M - -
Net income 2022 5 704 M - -
Net Debt 2022 20 694 M - -
P/E ratio 2022 32,5x
Yield 2022 1,86%
Capitalization 173 B 173 B -
EV / Sales 2022 5,89x
EV / Sales 2023 5,53x
Nbr of Employees 90 000
Free-Float 99,7%
Chart MEDTRONIC PLC
Duration : Period :
Medtronic plc Technical Analysis Chart | MDT | IE00BTN1Y115 | MarketScreener
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 28
Last Close Price 128,91 $
Average target price 145,92 $
Spread / Average Target 13,2%
EPS Revisions
Managers and Directors
Geoffrey Straub Martha Chairman & Chief Executive Officer
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Laura Mauri Chief Clinical & Regulatory Officer, Senior VP
Richard E. Kuntz Chief Medical & Scientific Officer, Senior VP
Gregory L. Smith Executive VP-Global Operations & Supply Chain
Sector and Competitors
1st jan.Capi. (M$)
MEDTRONIC PLC9.13%172 048
ABBOTT LABORATORIES14.28%221 833
BECTON, DICKINSON AND COMPANY3.51%74 382
HOYA CORPORATION28.03%62 177
SARTORIUS STEDIM BIOTECH84.00%57 875
ALIGN TECHNOLOGY, INC.32.71%56 031